Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 12/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.63 |
| ▸ | THPO | P40225 | 1/20 | 0.63 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.63 |
| ▸ | ADORA3 | P0DMS8 | 12/20 | 0.62 |
| ▸ | ADORA2A | P29274 | 9/20 | 0.62 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.61 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7442349 | 0.99 | ADORA1 (0.64) | ADORA1CYP1A2CYP3A4CYP2D6PKM | |
| SCHEMBL21348744 | 0.93 | YTHDC1 (0.66) | ADORA1CYP1A2CYP3A4CYP2D6PKM | |
| SCHEMBL3451170 | 0.83 | CTSL (0.68) | ADORA1CYP1A2ADORA3ADORA2AADORA2B | |
| SCHEMBL5263284 | 0.82 | ADORA3 (0.57) | ADORA1ADORA3ADORA2AYTHDC1ADORA2B | |
| SCHEMBL13057358 | 0.82 | CDK2 (0.61) | ADORA1ADORA3ADORA2AADORA2B | |
| SCHEMBL1711428 | 0.81 | YTHDC1 (0.57) | ADORA1CYP1A2CYP3A4CYP2D6PKM | |
| SCHEMBL3141354 | 0.79 | PDE4A (0.65) | ADORA1CYP1A2CYP3A4CYP2D6PKM | |
| SCHEMBL14564552 | 0.79 | ADORA1 (0.97) | ADORA1CYP1A2CYP3A4CYP2D6PKM | |
| SCHEMBL183730 | 0.78 | AXL (0.48) | ADORA1CYP1A2CYP3A4CYP2D6PKM | |
| SCHEMBL1322040 | 0.77 | ADORA1 (1.00) | ADORA1CYP1A2CYP3A4CYP2D6PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106456580-B | Heterocyclic hydroxamic acids as protein deacetylase inhibitors and dual protein deacetylase-protein kinase inhibitors and methods of use thereof | 科罗拉多州立大学董事会法人团体 | 2020-09-04 | — | — | CN | disclosed |
| US-RE47690-E1 | Heterocyclic hydroxamic acids as protein deacetylase inhibitors and dual protein deacetylase-protein kinase inhibitors and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2019-11-05 | — | — | US | disclosed |
| US-RE47690-E1 | Heterocyclic hydroxamic acids as protein deacetylase inhibitors and dual protein deacetylase-protein kinase inhibitors and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2019-11-05 | — | — | US | disclosed |
| US-20180044352-A1 | Heterocyclic Hydroxamic Acids as Protein Deacetylase Inhibitors and Dual Protein Deacetylase-Protein Kinase Inhibitors and Methods of Use Thereof | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2018-02-15 | — | — | US | disclosed |
| US-20180044352-A1 | Heterocyclic Hydroxamic Acids as Protein Deacetylase Inhibitors and Dual Protein Deacetylase-Protein Kinase Inhibitors and Methods of Use Thereof | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2018-02-15 | — | — | US | disclosed |
| US-9840520-B2 | Heterocyclic hydroxamic acids as protein deacetylase inhibitors and dual protein deacetylase-protein kinase inhibitors and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2017-12-12 | — | — | US | disclosed |
| US-9840520-B2 | Heterocyclic hydroxamic acids as protein deacetylase inhibitors and dual protein deacetylase-protein kinase inhibitors and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2017-12-12 | — | — | US | disclosed |
| EP-2402341-B1 | Purinyl derivatives and their use as potassium channel modulators | SANIONA AS (DK) | 2017-10-25 | — | — | EP | disclosed |
| EP-2402341-B1 | Purinyl derivatives and their use as potassium channel modulators | SANIONA AS (DK) | 2017-10-25 | — | — | EP | disclosed |
| EP-2142546-B1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | SANIONA AS (DK) | 2017-06-07 | — | — | EP | disclosed |
| US-20100120797-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2010-05-13 | — | — | US | disclosed |
| US-20100120797-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2010-05-13 | — | — | US | disclosed |
| US-20100105705-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2010-04-29 | — | — | US | disclosed |
| US-20100105705-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2010-04-29 | — | — | US | disclosed |
| US-20100105705-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2010-04-29 | — | — | US | disclosed |
| CN-101646669-A | Purinyl derivatives and their use as potassium channel modulators | NEUROSEARCH AS DK | 2010-02-10 | — | — | CN | disclosed |
| EP-2142545-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NeuroSearch A/S (DK) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008116909-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008116910-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008116910-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105705-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNJ5, KCNJ3 | ADORA1 341/4885CYP1A2 3789/4885CYP3A4 3503/4885 |
| US-20100120797-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNJ5, KCNJ3 | ADORA1 341/4885CYP1A2 3789/4885CYP3A4 3503/4885 |
| US-20180044352-A1 | Heterocyclic Hydroxamic Acids as Protein Deacetylase Inhibitors and Dual Protein Deacetylase-Protein Kinase Inhibitors and Methods of Use Thereof | TTK, HDAC1, HDAC6 | ADORA1 4373/4885CYP1A2 4304/4885CYP3A4 4484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.